We Can Medicines Co., Ltd. (TPEX:6929)
Taiwan
· Delayed Price · Currency is TWD 27.10
+0.10 (0.37%)
Apr 29, 2026, 1:17 PM CST
We Can Medicines Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Revenue | 3,222 | 3,269 | 3,123 | 3,303 | 2,794 | Upgrade
|
| Revenue Growth (YoY) | -1.45% | 4.69% | -5.45% | 18.20% | 4.77% | Upgrade
|
| Cost of Revenue | 2,154 | 2,165 | 2,099 | 2,191 | 1,878 | Upgrade
|
| Gross Profit | 1,068 | 1,104 | 1,023 | 1,112 | 916.55 | Upgrade
|
| Selling, General & Admin | 1,136 | 1,154 | 1,002 | 990.45 | 886.13 | Upgrade
|
| Operating Expenses | 1,136 | 1,154 | 999.52 | 994.39 | 886.22 | Upgrade
|
| Operating Income | -68.02 | -50.01 | 23.94 | 117.2 | 30.33 | Upgrade
|
| Interest Expense | -25.6 | -27.43 | -23.46 | -19.09 | -14.43 | Upgrade
|
| Interest & Investment Income | 1.3 | 1.25 | 0.62 | 0.24 | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.01 | -0.01 | 1.64 | -0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 26.75 | 31.56 | 25.28 | 31.91 | 24.76 | Upgrade
|
| EBT Excluding Unusual Items | -65.58 | -44.62 | 26.37 | 131.9 | 40.45 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.47 | 0.37 | - | 0.11 | 0.19 | Upgrade
|
| Gain (Loss) on Sale of Assets | -7.08 | -0.14 | -2.77 | -7.2 | -1.85 | Upgrade
|
| Asset Writedown | -3.8 | -4.4 | -2 | -3.68 | - | Upgrade
|
| Other Unusual Items | 2.8 | 0.5 | - | - | - | Upgrade
|
| Pretax Income | -73.19 | -48.29 | 21.6 | 121.13 | 38.79 | Upgrade
|
| Income Tax Expense | 0.02 | -1.12 | 6.8 | 21.08 | - | Upgrade
|
| Net Income | -73.21 | -47.18 | 14.8 | 100.05 | 38.79 | Upgrade
|
| Net Income to Common | -73.21 | -47.18 | 14.8 | 100.05 | 38.79 | Upgrade
|
| Net Income Growth | - | - | -85.20% | 157.91% | -9.16% | Upgrade
|
| Shares Outstanding (Basic) | 45 | 43 | 40 | 40 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 43 | 42 | 42 | 40 | Upgrade
|
| Shares Change (YoY) | 3.56% | 2.86% | 1.26% | 4.31% | 24.84% | Upgrade
|
| EPS (Basic) | -1.63 | -1.09 | 0.37 | 2.50 | 0.97 | Upgrade
|
| EPS (Diluted) | -1.63 | -1.09 | 0.35 | 2.40 | 0.97 | Upgrade
|
| EPS Growth | - | - | -85.42% | 147.46% | -27.08% | Upgrade
|
| Free Cash Flow | 204.5 | 196.73 | 47.29 | 224.13 | 117.58 | Upgrade
|
| Free Cash Flow Per Share | 4.54 | 4.53 | 1.12 | 5.37 | 2.94 | Upgrade
|
| Dividend Per Share | - | - | 0.270 | - | - | Upgrade
|
| Gross Margin | 33.15% | 33.77% | 32.77% | 33.66% | 32.80% | Upgrade
|
| Operating Margin | -2.11% | -1.53% | 0.77% | 3.55% | 1.08% | Upgrade
|
| Profit Margin | -2.27% | -1.44% | 0.47% | 3.03% | 1.39% | Upgrade
|
| Free Cash Flow Margin | 6.35% | 6.02% | 1.51% | 6.79% | 4.21% | Upgrade
|
| EBITDA | -0.8 | 18.4 | 84.94 | 175.47 | 76.28 | Upgrade
|
| EBITDA Margin | -0.03% | 0.56% | 2.72% | 5.31% | 2.73% | Upgrade
|
| D&A For EBITDA | 67.23 | 68.41 | 61 | 58.27 | 45.95 | Upgrade
|
| EBIT | -68.02 | -50.01 | 23.94 | 117.2 | 30.33 | Upgrade
|
| EBIT Margin | -2.11% | -1.53% | 0.77% | 3.55% | 1.08% | Upgrade
|
| Effective Tax Rate | - | - | 31.47% | 17.40% | - | Upgrade
|
| Advertising Expenses | 1.92 | - | - | 903.85 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.